Navigation Links
ViroPharma to Present at Several Upcoming Healthcare Conferences
Date:9/3/2009

EXTON, Pa., Sept. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting in four upcoming healthcare investment conferences during the month of September.

Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Rodman & Renshaw 11th Annual Global Healthcare Conference at 11:15 A.M. ET on Thursday, September 10, 2009. The conference is being held at the New York Palace Hotel.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Thomas Weisel Partners 2009 Global Healthcare Conference at 8:00 A.M. ET on Thursday, September 10, 2009. The conference is being held at the Four Seasons Hotel in Boston.

William Roberts, vice president, corporate communications will present at the BioCentury Newsmakers in the Biotech Industry Conference at 3:30 P.M. ET on Wednesday, September 16, 2009. The conference is being held at the Millennium Broadway Hotel in New York City.

Mr. Milano will also present at the ThinkEquity 6th Annual Growth Conference at 5:15 P.M. ET (2:15 P.M. PT) on Wednesday, September 16, 2009. The conference is being held at the St. Regis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
2. ViroPharma to Present at Two June Healthcare Conferences
3. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
6. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
7. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
8. ViroPharma to Present at Three November Healthcare Conferences
9. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
10. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
11. ViroPharma to Present at Three October Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... the re-launch of “Crosswalk Insight: Oncology™” (Crosswalk), a unique precision medicine knowledge visualization ... can now be accessed through Inspirata’s diagnostic cockpit and is downloadable as an ...
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath ... associated with peritoneal dialysis, announced today that it has published the result of ... in Peritoneal Dialysis International (PDI), the official Journal of the International Society ...
(Date:2/20/2017)...  Atrius Health and IBM (NYSE: IBM ... to develop a cloud based service designed to ... view of the multiple influences on an individual,s ... be designed to support shared decision making between ... nonprofit healthcare organization with 875 physicians caring for ...
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT ... the Center for International Blood & Marrow Transplant Research (CIBMTR) will take place ... , The combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):